Compare ONB & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONB | KYMR |
|---|---|---|
| Founded | 1834 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.6B |
| IPO Year | 2012 | 2020 |
| Metric | ONB | KYMR |
|---|---|---|
| Price | $27.23 | $117.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 26 |
| Target Price | $27.25 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 4.5M | 622.5K |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $125,616,000.00 | $39,211,000.00 |
| Revenue This Year | $27.93 | $10.61 |
| Revenue Next Year | $5.10 | $8.17 |
| P/E Ratio | $45.88 | ★ N/A |
| Revenue Growth | ★ 6.07 | N/A |
| 52 Week Low | $19.39 | $39.84 |
| 52 Week High | $27.36 | $130.05 |
| Indicator | ONB | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 64.79 |
| Support Level | $25.55 | $108.87 |
| Resistance Level | $27.34 | $120.37 |
| Average True Range (ATR) | 0.43 | 4.17 |
| MACD | -0.01 | 0.68 |
| Stochastic Oscillator | 85.08 | 99.46 |
Old National Bancorp is a provider of lending and deposit services. The bank offers comprehensive wealth management, trust, investment advisory, brokerage, and foreign currency services. For businesses, it provides treasury management, merchant, and capital markets services as well as community development lending and equity investment solutions intended to produce jobs and revitalize its communities. It earns interest income on loans as well as fee income from the origination of loans and from providing other services to its clients.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.